©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1891-1899
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1891
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1891
Table 2 Baseline characteristics of MUTYH-associated polyposis patients (n = 38)
| Characteristics | n (%) |
| Male | 28 (74) |
| Age at diagnosis (yr), mean ± SD | 48 ± 10 |
| Pathogenic MUTYH variants | |
| Homozygotes | 7 (18) |
| Compound heterozygotes | 31 (82) |
| Most reported variant1 | c.452A>G;p.Tyr151Cys |
| Colectomy | |
| No | 11 (29) |
| Total | 14 (37) |
| Subtotal | 13 (34) |
| Colorectal cancer | 18 (47) |
| Duodenal adenomas | 32 (9) |
| Spigelman stage I | 2 (6) |
| Spigelman stage II | 1 (3) |
| Spigelman stage III | 0 |
| Spigelman stage IV | 0 |
| Extracolic tumors | 11 (29) |
| Thyroid carcinoma/papillary thyroid carcinoma | 4 (36) |
| Breast cancer | 2 (18) |
| Small bowel cancer | 2 (18) |
| Bladder cancer | 1 (9) |
| Desmoid tumor | 1 (9) |
| Kidney tumor | 1 (9) |
- Citation: Sanchez-Mete L, Mosciatti L, Casadio M, Vittori L, Martayan A, Stigliano V. MUTYH-associated polyposis: Is it time to change upper gastrointestinal surveillance? A single-center case series and a literature overview. World J Gastrointest Oncol 2023; 15(11): 1891-1899
- URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1891.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1891